Back to News & Events

Dr. Louis A. Peña appointed Director, Program in Life Sciences Innovation and Entrepreneurship & Associate Professor of Practice

The Center for Biotechnology has announced the appointment of Dr. Louis A. Peña as Director of the new Program in Life Sciences Innovation and Entrepreneurship. Additionally, Dr. Peña has been appointed as Associate Professor of Practice in the Department of Biomedical Engineering and the College of Business at Stony Brook University.

The Professor of Practice will steward the University’s Advanced Graduate Certificate in Life Science Innovation and Entrepreneurship, which was established under Empire State Development’s Life Science Entrepreneur Development award, and further develop educational and experiential learning initiatives. The Director of the Program in Life Sciences Innovation and Entrepreneurship will build upon the Center’s efforts to synergize technology and business accelerator activities with opportunities for students to gain real-world technology commercialization experience.

Prior to joining the Center for Biotechnology and Stony Brook University, Dr. Peña held leadership positions in both industry and academia. He is experienced with startup and early stage companies. Commercializing scientific discoveries he made at Brookhaven National Laboratory, Dr. Peña co-developed a biotech startup that took a biomaterial from idea to clinical trials and acquisition. He later served as Chief Scientific Officer of a biopharma Contract Research Organization. Dr. Peña has also consulted for technology startups in bioagriculture, medical devices, medical imaging, and energy, supporting technology assessment, market assessment, and business strategy.

“We are excited to have Louis join the Center for Biotechnology and Stony Brook University to further our efforts of expanding entrepreneurial education in the life sciences” Diane Fabel, Director of Operations at the Center for Biotechnology said. She continued “His industry involvement, coupled with his academic experiences allow him to bring a unique perspective to the role and for students in our programs to benefit from his real-world experience.”

“I am very happy to join the team at the Center for Biotechnology and my colleagues at Stony Brook University. The Center has a great, established foundation of commercialization and education in this sector and I’m eager to further develop these unique and critical programs” Dr. Peña said. “Our goal is to bolster the life science commercialization knowledge of students graduating from New York universities. At one level, this will help entrepreneurs gain the mix of skills and expertise needed to successfully guide innovative life science startups along the path to commercial viability. At a broader level, this will help with the biotech workforce development of our region and state for those who may not want to start companies but want to understand the sector in great depth so they can secure well-paying and/or leadership positions in this sector.”

Download a PDF of the announcement here.

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4804
                    [post_author] => 4
                    [post_date] => 2025-03-20 12:10:54
                    [post_date_gmt] => 2025-03-20 16:10:54
                    [post_content] => 

The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.

The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.

The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.

Learn more about the program, get information session details and access the full request for proposals here: https://centerforbiotechnology.org/what-we-do/technology-development/reach/

[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards [post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => news-reach25 [to_ping] => [pinged] => [post_modified] => 2025-03-24 12:11:36 [post_modified_gmt] => 2025-03-24 16:11:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4804 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 4488 [post_author] => 4 [post_date] => 2024-10-24 10:45:00 [post_date_gmt] => 2024-10-24 14:45:00 [post_content] =>

Governor Kathy Hochul has unveiled plans for New York BioGenesis Park, a groundbreaking $430 million Cell and Gene Therapy (CGT) Innovation Hub in Nassau County, Long Island. To be developed by The Albanese Organization, Inc., this state-of-the-art facility would catalyze CGT research, development, clinical manufacturing, and commercialization across New York State. With a historic $150 million state investment—the largest nationwide for a cell and gene therapy hub—NYBGP would accelerate the delivery of new therapies from lab to patient in New York's diverse communities. This transformative hub aims to establish New York as the leading global destination for CGT innovation, driving economic growth, attracting top talent, and revolutionizing patient care statewide and beyond.

The Center for Biotechnology is thrilled to be counted as a partner in this effort, and is looking forward to working with our colleagues in the initiative to help catalyze and accelerate life-changing therapies.

New York BioGenesis Park is envisioned as a cutting-edge, full-service campus dedicated to advancing cell and gene therapies and accelerating their commercialization. At full build-out, the 700,000-square-foot park would create an end-to-end Cell and Gene Therapy innovation and supply center, featuring interconnected areas for public engagement, research, manufacturing, and collaboration.

A cornerstone of New York BioGenesis Park is its incubator, supported by a $50 million investment from ESD's Long Island Investment Fund. This facility will empower early-stage therapeutic developers by offering state-of-the-art wet lab space, shared equipment, office space, and other essential resources. This nurturing environment will provide Cell and Gene Therapy companies with access to specialized equipment, mentoring, and stage-appropriate financial guidance. As a critical component of New York BioGenesis Park, the incubator is poised to catalyze the growth of promising Cell and Gene Therapy companies by providing them with resources and support, unlocking their potential for innovation and success.

New York BioGenesis Park would foster strong ties with academic and medical institutions throughout New York, creating a robust ecosystem for Cell and Gene Therapy innovation. Collaborating with the Empire State Cellular Therapy Consortium and world-class institutions like Cold Spring Harbor Laboratory, the Feinstein Institutes, Northwell Health, Roswell Park, Stony Brook University, Weill Cornell, Columbia University and others around the state, New York BioGenesis Park would enhance research synergies and accelerate medical breakthroughs. This ecosystem would bring together experts in advanced Cell and Gene Therapy therapies, offering specialized facilities, services, and resources to both tenants and collaborating institutions. By facilitating cutting-edge science, innovative technology development and novel approaches to clinical trials, New York BioGenesis Park would ensure New York's institutions remain globally competitive in groundbreaking Cell and Gene Therapy research and commercialization.

Read the press release of Governor Hochul's announcement here:
https://www.governor.ny.gov/news/governor-hochul-launches-next-phase-long-islands-nation-leading-cell-and-gene-therapy

[post_title] => Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park. [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-to-be-location-for-nation-leading-cell-and-gene-therapy-innovation-hub-new-york-biogenesis-park [to_ping] => [pinged] => [post_modified] => 2025-02-26 16:35:20 [post_modified_gmt] => 2025-02-26 21:35:20 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4488 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 2733 [post_author] => 3 [post_date] => 2017-06-15 07:00:53 [post_date_gmt] => 2017-06-15 07:00:53 [post_content] =>

Awards Support Innovative Research Collaborations Between Academic Faculty and Regional Bioscience Companies

The Center for Biotechnology at Stony Brook University has announced the recipients of the 2017-2018 Applied Research & Development (ARAD) awards. The ARAD Program is designed to help bridge the gap between the early-stage technology discovery and development capabilities of the academic community, and the later-stage commercial development interests of the bioscience industry. The program currently provides matching funds on a competitive basis to support collaborations between Stony Brook University faculty and New York State corporate partners in all areas of medical biotechnology. The primary interest is in supporting development of technologies that will help companies hit commercially relevant milestones, and that have the potential to positively impact the New York State economy. Projects supported this year include the furthered development of an ICU temporary pacemaker, a novel Lymphoma treatment, a novel synthetic peptide based therapeutic for Osteoporosis, further development of an fMRI Dynamic Phantom, development of novel vaccines, third generation taxoid based nanomedicine for chemoresistant cancer, development of a polymeric heart valve, a drug delivery technology for treatment of gastrointestinal diseases, and the development of skin brightening agents. “The Center’s Applied Research and Development Program speaks to the core of what our organization does – collaborate with New York State companies to help them develop commercially promising technologies that will lead to strategic partnerships, investment, corporate revenues, and job creation” said Diane Fabel, Director of Operations for the Center for Biotechnology. “Our academic institutions are incredible resources for bioscience companies to tap into when it comes to technology development, and promoting interactions between the two helps fuel the overall bioscience ecosystem in the region.” The ARAD Program is part of a suite of programs and services provided by the Center for Biotechnology (CFB) focused on accelerating the development of biomedical technologies in order to have a positive impact on human health and society. The CFB is also the lead administrative institution for the Long Island Bioscience Hub (LIBH) an NIH-designated Research Evaluation and Commercialization Hub (REACH) established with a National Institutes of Health grant in 2015. 2017-2018 Applied Research and Development Awards  "Synthetic Osteogenic Peptide for Treatment of Osteoporosis" Ajes Life Sciences & Dr. Srinivas Pentyala "fMRI Dynamic Phantom for Improved Detection of Resting State Brain Networks" ALA Scientific Instruments & Dr. Helmut Strey "Continued Development of ICU Temporary Pacemaker" Avery Biomedical Inc & Dr. Wei Lin "Novel Pleiotropic Skin Brightening Agents" Biocogent, LLC & Dr. Sanford Simon "In vivo Testing of Vaccine Candidates" Codagenix, Inc & Dr. Eckard Wimmer "A Novel Polymeric Valve for Transcatheter Aortic Valve Replacement" Polynova Cardiovascular, Inc. & Dr. Danny Bluestein "Imaging the Targeted Delivery of Biologic Agents to the Colon for Local Therapeutic Action" Symbiotic Health Inc. & Dr. Peter M. Smith-Jones "Eradication of an Oncogenic Herpesvirus as a Novel Intervention for Lymphoma" Theragnostic Technologies, Inc. & Dr. Laurie T. Krug "Novel Cancer Stem Cell Cytotoxic Agent: Nano-Formulation IND-Enabling Studies" TargaGenix Inc. & Dr. Galina Botchkina Download a PDF of the press release here.   [post_title] => Annual Applied Research And Development Awards Announced [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => arad-2017 [to_ping] => [pinged] => [post_modified] => 2017-09-05 13:19:55 [post_modified_gmt] => 2017-09-05 13:19:55 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/?p=2733 [menu_order] => 142 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 1475 [post_author] => 3 [post_date] => 2015-03-26 16:37:02 [post_date_gmt] => 2015-03-26 16:37:02 [post_content] => Eavesdropping on Investors' Closed Door Discussions" 1st Pitch Life Sciences Meeting Tuesday, April 14, 2015 5:30pm - 8:30pm Hear what happens after a start-up company presents to an investor group. Usually after the company representatives leave the room the investors have a private discussion to decide whether the opportunity merits further investigation and possible investment. 1st Pitch Life Science offers presenters and audience members the chance to hear what happens in those closed-door discussion, and to learn what really matters to investors. 1st Pitch Life Science is organized by MABA (Mid Atlantic Bio Angels www.bioangels.net), a life science investor group, to encourage and educate aspiring life science entrepreneurs who know they may be too early or not fully prepared to seek investment but want the opportunity to practice their pitch and to receive constructive criticism from experienced and knowledgeable professionals. To Register: https://1stpitchapril2015.eventbrite.com When: Tuesday, April 14th, 2015 5:30pm : Registration & Networking 6:00 - 8:00pm : Program 8:00 - 8:30pm : Networking Where:** Please note new location** New York Genome Center 101 Avenue of the Americas New York, NY 10013   [post_title] => 1st Pitch Life Sciences Meeting - April 14 [post_excerpt] => [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => 1st-pitch-life-sciences-meeting-april-14 [to_ping] => [pinged] => [post_modified] => 2016-03-02 18:13:17 [post_modified_gmt] => 2016-03-02 18:13:17 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1475 [menu_order] => 207 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [4] => WP_Post Object ( [ID] => 1455 [post_author] => 3 [post_date] => 2015-03-16 19:45:43 [post_date_gmt] => 2015-03-16 19:45:43 [post_content] => Traverse Biosciences, founded by Joseph Scaduto - one of the Center for Biotechnology's first BioEntrepreneurs-in-Residence, announced today that it has executed an exclusive, worldwide license agreement with the Research Foundation for the State University of New York (RF/SUNY) for access to the animal health applications of a proprietary library of polyenolic zinc-binding agents. The license agreement also extends Traverse Biosciences the exclusive option to license the human health applications of these promising drug candidates. The drug compounds were invented by Lorne Golub, DMD, MD (Honorary), Distinguished Professor in the Department of Oral Biology and Pathology in the Stony Brook University School of Dental Medicine, and Francis Johnson, PhD, President of Chem-Master International Inc. and Professor of Chemistry and Pharmacology at Stony Brook. The drugs were developed in concert with the the Center for Biotechnology at Stony Brook University. The Center provided financial support to help the inventors develop their lead compound and for follow-on animal studies. Click to read the press releases from Stony Brook University and Traverse Biosciences. [post_title] => Traverse Biosciences Executes Exclusive, Worldwide License Agreement [post_excerpt] => Traverse Biosciences, founded by Joseph Scaduto - one of the Center for Biotechnology's first BioEntrepreneurs-in-Residence, has executed an exclusive, worldwide license agreement with the Research Foundation for the State University of New York (RF/SUNY). [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => traverse-biosciences-executes-exclusive-worldwide-license-agreement [to_ping] => [pinged] => [post_modified] => 2015-03-16 19:46:46 [post_modified_gmt] => 2015-03-16 19:46:46 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1455 [menu_order] => 209 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 5 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4804 [post_author] => 4 [post_date] => 2025-03-20 12:10:54 [post_date_gmt] => 2025-03-20 16:10:54 [post_content] =>

The Center for Biotechnology is pleased to announce a request for proposals for our Research Evaluation and Commercialization Hub (REACH) award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) Details on the full funding program overview and proposal guidelines can be found here.

The development of promising innovations often stalls due to limited early-stage funding to address translational uncertainties. The Center for Biotechnology's Research Evaluation and Commercialization Hub (REACH) award program bridges the translation gap between biomedical discovery and their development toward commercial goals. Program funding is intended to determine feasibility, develop proof-of-concept, and ultimately lead to follow-on funding, a strategic partnership, or company formation.

The REACH program supports faculty and postdoctoral researchers in translating bio-based, bio-convergence, and bio-medical research discoveries by providing targeted funding and strategic guidance to bridge the translation gap between discovery and development for commercialization.

Learn more about the program, get information session details and access the full request for proposals here: https://centerforbiotechnology.org/what-we-do/technology-development/reach/

[post_title] => Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards [post_excerpt] => The Center for Biotechnology is pleased to announce a request for proposals for our REACH award program. Awards will be in two categories: Feasibility ($50k/12mo) and Proof of Concept ($100K/12 mo.) [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => news-reach25 [to_ping] => [pinged] => [post_modified] => 2025-03-24 12:11:36 [post_modified_gmt] => 2025-03-24 16:11:36 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4804 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 265 [max_num_pages] => 89 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

Funding Opportunity: Research Evaluation and Commercialization Hub (REACH)Awards

More Information

Long Island to be location for Nation-Leading Cell and Gene Therapy Innovation Hub: New York BioGenesis Park.

More Information

Annual Applied Research And Development Awards Announced

More Information

1st Pitch Life Sciences Meeting – April 14

More Information

Traverse Biosciences Executes Exclusive, Worldwide License Agreement

More Information